Methods Study subjects This was a single-center, randomized, double-blind, placebo-controlled study. Postmenopausal Japanese women between the ages of 60 and 79 years were eligible. The inclusion criteria included postmenopausal women without concomitant allergic diathesis, secondary osteoporosis, past histories of extensive abdominal surgery, calcium abnormalities, drug use which may affect bone metabolism, or bone fractures within 12 weeks prior to the study. Study drug Teriparatide and the placebo, both of which were identical in appearance, were supplied by Asahi Kasei Pharma Corporation.
Study design Eligible women were randomized before receiving a single subcutaneous injection of placebo or teriparatide (28.2 or 56.5 μg). On the first day of administration (day 1), baseline (0 h) examinations were performed at 0800 h. Teriparatide
or placebo was administered immediately after collection H 89 supplier of baseline blood and urine samples. Blood samples were collected at 15, 30, 45, 60, 90, 120, 180, 240, 360, and 720 min after the injection. Urine samples were collected 120, 240, 360, and 720 min after the injection on day 1. Subsequent blood and urine samples were collected at 0800 h on day 2 and in the morning on days 4, 6, 8, 11, 13, and 15. Outcomes measures PK, safety, and changes in calcium metabolism and bone turnover markers were measured. Teriparatide acetate plasma concentrations were measured at Daiichi Pure Chemicals Co., Ltd. (Tokyo, Japan) Doramapimod cost using a rat PTH immunoradiometric assay (IRMA) kit (Immutopics, Inc., San Clemente, CA, USA) with a range of 10 to 1,000 pg/mL. Measurement of the markers of calcium metabolism [serum calcium (Ca), inorganic phosphorus (P), and urinary excretion of Ca and P] was performed at Mitsubishi Chemical Medience Co. (Tokyo, Japan). Serum-corrected Ca was calculated by the value of serum albumin [12]. Serum levels of intact PTH were measured by an however electrochemiluminescence immunoassay (Roche Diagnostics K.K., Tokyo, Japan). 1,25-Dihydroxy vitamin D (1,25(OH)2D) was measured by a radio receptor assay (TFB Inc., Tokyo, Japan), and 25-hydroxy
vitamin D (25(OH)D) was measured by a competitive protein-binding assay (Mitsubishi Chemical Medience); the inter-assay coefficient of variation (CV) was 11.3–13.2 and 3.7–9.9 %, respectively. Serum levels of the bone turnover markers osteocalcin and P1NP (both bone formation markers) were measured by BGP-IRMA (Mitsubishi Chemical Medience, Tokyo, Japan) and bone radioimmunoassay (Orion Diagnostic, Espoo, Finland), respectively (inter-assay CV, 4.7–7.6 and 2.7–5.0 %, respectively). Serum cross-linked N-telopeptide of type I collagen (NTX, Osteomark, Inverness Medical Innovations Inc, Waltham, MA, USA) was measured by ELISA, and urinary cross-linked C-telopeptide of type I collagen (CTX, Fujirebio Inc., Tokyo, Japan) was measured by ELISA; both are bone resorption markers (inter-assay CV, 6.9–11.1 and 2.4–9.0 %, respectively).